Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock
November 09, 2021 21:30 ET
|
Avenue Therapeutics
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
October 25, 2021 07:00 ET
|
Avenue Therapeutics
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
June 14, 2021 07:00 ET
|
Avenue Therapeutics
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol
April 13, 2021 06:30 ET
|
Avenue Therapeutics
NEW YORK, April 13, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
December 18, 2020 08:00 ET
|
Avenue Therapeutics
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced...
Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
December 18, 2020 08:00 ET
|
Avenue Therapeutics
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced...
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
December 17, 2020 07:00 ET
|
Avenue Therapeutics
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a...
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
October 12, 2020 06:30 ET
|
Avenue Therapeutics
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Publication of a Review of IV Tramadol
September 09, 2020 08:00 ET
|
Avenue Therapeutics
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
August 14, 2020 07:30 ET
|
Avenue Therapeutics
NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...